A Historic Step for Eye Health:
For decades, a diagnosis of glaucoma or optic neuropathy has carried a sobering truth: once the nerves connecting your eye to your brain are damaged, they don’t grow back. But a landmark announcement from Life Biosciences may signal the beginning of a new chapter in how we approach age-related vision loss — and aging itself.
In January 2026, the U.S. FDA cleared Life Biosciences’ Investigational New Drug (IND) application for ER-100, making it the first ever cellular rejuvenation therapy using epigenetic reprogramming to receive FDA clearance to enter human clinical trials. That’s not just a milestone for the company — it’s a milestone for medicine.
What Is ER-100, and How Does It Work?
ER-100 was developed using Life Biosciences’ Partial Epigenetic Reprogramming (PER) platform, which aims to restore aged or injured cells to a younger state by modifying the epigenome — the biochemical markers that regulate gene expression without altering the underlying DNA sequence. In plain terms: rather than editing your genes, this therapy essentially tells your cells to behave like younger, healthier versions of themselves.
The approach centers on three so-called Yamanaka factors, OCT-4, SOX-2, and KLF-4, proteins known to play a key role in cellular “youthfulness.” Delivered by injection directly into the eye, ER-100 has shown promising safety and efficacy results in preclinical animal studies.
Why Optic Neuropathies?
Optic neuropathies are a group of disorders characterized by the irreversible death of retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs cannot naturally regenerate, their loss results in permanent vision impairment.
Two conditions are the focus of the upcoming Phase 1 trial: open-angle glaucoma, a leading cause of blindness worldwide, and non-arteritic anterior ischemic optic neuropathy (NAION) — often called “stroke of the eye,” the most common acute optic neuropathy in adults over fifty, involving sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments.
Current standards of care fail to address the underlying neuronal degeneration, leaving a significant unmet medical need for disease-modifying therapies that can directly protect or regenerate RGCs. ER-100 is designed to do exactly that.
What Comes Next?
The Phase 1 trial will enroll patients with both conditions to evaluate safety, tolerability, immune responses, and effects on vision. While this is still an early-stage study, and a long road remains before any therapy reaches patients broadly, the FDA clearance is a meaningful validation of the science behind cellular rejuvenation.
As Life Biosciences’ Chief Scientific Officer Sharon Rosenzweig-Lipson noted, years of research and rigorous primate studies demonstrating controlled gene expression, restoration of methylation patterns, and improved visual function laid the foundation for this moment. The goal, ultimately, is straightforward even if the biology is complex: to give people back their sight, and to chip away at the diseases that rob us of our health as we age.
This is one to watch.
This topic is featured in Great News podcast episode 37
.
The Great News Podcast is your source for positive news, inspiring stories, and good news from around the world. We skip the doom and gloom of mainstream media to focus on scientific breakthroughs, environmental wins, and the inspiring news that proves the world is getting better. Join Andrew McGivern for a dose of optimism and uplifting stories that will change your perspective on human progress.
It is easy to find the
Keep looking for the good in the world, because it is not only there – its everywhere.
This episode is brought to you by the Daily Quote. The podcast designed to kickstart your day in a positive way.Today, we’re exploring how scientists are turning back the clock on aging cells, printing infrastructure beneath the ocean waves, and building a ”heart-on-a-chip” to revolutionize medicine.And don't forget to stick around to the end for the speed round for even more great news!The First Epigenetic Reprogramming Therapy Enters Human TrialsThe World’s First Underwater 3D Concrete Printer
The Tiny Chip That Could Change Heart Medicine ForeverThe Horse H12 is a Cleaner Combustion Engine
Alright, Let's dive into the speed round for even more great news:
The greater Bermuda snail, once feared extinct, is officially safe after conservationists bred and released over 100,000 molluscs.
Researchers at Texas A&M have developed clay-based bandages that can be injected into deep wounds to stop severe internal bleeding, reducing clotting time by 70%.
A new blood test can now predict when Alzheimer’s symptoms will begin—with an accuracy within three to four years—long before memory problems appear.
Scientists are testing CAR T cell therapy to target and destroy the amyloid plaques in the brain that cause Alzheimer's, successfully reshaping the immune landscape in preclinical models.
And my favorite quote of the day from the Daily Quote podcast this week is from James Clear who said,
“Every action you take is a vote for the type of person you wish to become.”
Start your day with an inspiring quote every single day with the Daily Quote – available in your favourite podcast app.
From rejuvenating cells to printing structures underwater, today’s stories prove that those seeds of innovation are growing into a brighter world.
I’m Andrew McGivern, and until next time, and there will be a next time, keep looking for the good in the world, because it’s everywhere.
Source: Life Biosciences
